ClinicalTrials.gg

Program

PD-L1 Inhibitor ABSK043

Also written as “ABSK043 oral capsule”, “ABSK043 in combination with Osimertinib” and “ABSK043 in combination with Glecirasib”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Neoplasms · Carcinoma, Transitional Cell, led by Abbisko Cayman.

Furthest: phase 2, since Oct 1, 20245 company-led studies, 5 open or runningNext primary completion: Jul 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Abbisko Cayman55 open or runningphase 2since Oct 1, 2024Jun 24, 2021Jul 30, 2027phase 1 · NCT04964375

Also a collaborator on its studies: AstraZeneca.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 24, 2021First study: phase 1 study in NeoplasmsFirst studyNCT04964375 · 102 enrolled · Australia, China
  2. Oct 1, 20242 phase 2 studiesNCT06632262, NCT06668103
  3. Sep 2, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07164170 · 86 planned · China
  4. Jul 14, 2026Phase 2 study in Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 PositiveNCT07710612 · 72 planned · China
  5. Nov 6, 2026Primary completion moved from 2022-10-23 to 2027-07-30Date moved laterphase 1 · +57 months · NCT04964375

Ahead

  1. Jul 30, 2027Primary completion: phase 1 study in NeoplasmsNCT04964375
  2. Dec 30, 2027Primary completion: phase 2 study in Non-Small Cell Lung Cancer With EGFR MutationNCT06668103
  3. Dec 30, 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07164170
  4. Nov 30, 2029Primary completion: phase 2 study in Carcinoma, Transitional CellNCT06632262

TargetBeta

CD274 →read by rule
“An orally available, small molecule inhibitor of the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), ”NCIt, by rule

Other programs on CD274

ProgramCompanyFurthest phaseStudies
durvalumabruleAstraZenecaphase 4102
adebrelimabruleJiangsu HengRui Medicinephase 351
pumitamigBioNTechphase 334
benmelstobartruleSino Biopharmaceuticalphase 333
retlirafusp alfaruleJiangsu HengRui Medicinephase 320
Anti-PD-L1 Antibody-drug Conjugate HLX43Fosun Pharmaphase 317
erfonrilimabruleAlphamab Oncologyphase 314
Anti-PD-L1/4-1BB Bispecific Antibody LBL-024rulenanjing-leads-biolabs-co-ltdphase 310
socazolimabruleLee's Pharmaceuticalphase 39
acasunlimabruleGenmabphase 36
sotiburafusp alfarulehuabo-biopharm-co-ltdphase 35
fetrastobart vedotinPfizerphase 32

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07710612Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive · China2Not yet recruitingDec 31, 202972
NCT07164170Carcinoma, Non-Small-Cell Lung · China2RecruitingDec 30, 202886
NCT06668103Non-Small Cell Lung Cancer With EGFR Mutation · China2RecruitingDec 30, 202754
NCT06632262Carcinoma, Transitional Cell · China2RecruitingNov 30, 2029202
NCT04964375Neoplasms · Australia, China1Active, not recruitingJul 30, 2027102

How it is read

Names in the registry

  • “ABSK043 oral capsule”, 1 entry
  • “ABSK043 in combination with Osimertinib”, 1 entry
  • “ABSK043 in combination with Glecirasib”, 1 entry
  • “ABSK043 in combination with Firmonertinib”, 1 entry
  • “ABSK061 + ABSK043”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.